HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications
HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications
Active, not recruiting · NCT02775227 · Registry updated 2020-08-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications | Digestive System Diseases, Digestive System Fistula, Digestive System Neoplasms, Fistula, Neoplasms by Site, Pancreatic Fistula, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 4 | 2020-08-24 | NCT02775227 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Helsinki University Central Hospital | 127 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Helsinki University Central Hospital | Helsinki | Finland | 17 |